Asahikawa Medical College, Hokkaido
Combinatory chemotherapy for metastatic colorectal cancer entered phase II trial
Published in Health Risk Factor Week, July 19th, 2005
"Irinotecan combined with continuous-infusion 5FU has been shown to be an effective and tolerable regimen in the treatment of MCRC. UFT during 5FU infusion enhances plasma 5FU concentration, mimics continuous 5FU infusion and delivers the drug to target tumor cells," researchers in Japan reported.
"We conducted a phase II trial of four-agent combined therapy for MCRC, giving patients (pts) intravenous irinotecan (30 mg/m2 on day 1), leucovorin (LV, 200 mg/m2 on day 1 and 2), 5FU...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
More Articles from Health Risk Factor Week
- Bar Ilan University, Ramat Gan
Recent findings in transplant medicine provide new insights - Columbia University
X-ray exposure during CT colonoscopy doesn't significantly raise cancer risks - Helsinn Healthcare SA
Helsinn and Angelini announce a license agreement for Aloxi in Portugal - Karolinska Institute, Stockholm
Case Method Learning-supported lipid-lowering strategy is cost-effective - Journal of Opioid Management
Article finds opioid abuse causes dependency in pregnancy - AARDEX Ltd
Pharmionics measures patient adherence to prescribed antimicrobial drug regimens - More from this issue of Health Risk Factor Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
